Cargando…
Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update
Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877216/ https://www.ncbi.nlm.nih.gov/pubmed/35214115 http://dx.doi.org/10.3390/pharmaceutics14020383 |
_version_ | 1784658367477710848 |
---|---|
author | Nair, Anroop B. Kumar, Sunil Dalal, Pooja Nagpal, Chahat Dalal, Sweta Rao, Rekha Sreeharsha, Nagaraja Jacob, Shery |
author_facet | Nair, Anroop B. Kumar, Sunil Dalal, Pooja Nagpal, Chahat Dalal, Sweta Rao, Rekha Sreeharsha, Nagaraja Jacob, Shery |
author_sort | Nair, Anroop B. |
collection | PubMed |
description | Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed. |
format | Online Article Text |
id | pubmed-8877216 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88772162022-02-26 Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update Nair, Anroop B. Kumar, Sunil Dalal, Pooja Nagpal, Chahat Dalal, Sweta Rao, Rekha Sreeharsha, Nagaraja Jacob, Shery Pharmaceutics Review Dermal disorders such as psoriasis and eczema are associated with modifications in the chemical and molecular composition of the skin. Clobetasol propionate (CP), a superpotent topical glucocorticoid, is widely used for the therapeutic management of various skin conditions, owing to its strong anti-inflammatory, antipruritic, vasoconstrictive, and antiproliferative activities. Safety studies demonstrated that CP is safer for a shorter period, however, with prolonged application, it shows secondary side effects such as photosensitivity, Cushing-like syndrome, allergic contact dermatitis, osteonecrosis, hypopigmentation, steroid acne, and skin atrophy. Therefore, the US FDA (United States Food and Drug Administration) has restricted the usage of CP to not more than 15 days. Research scientists addressed its several formulations and drug delivery issues, such as low water solubility, less stability, photodegradation, and poor absorption, by incorporating them into novel nanobased delivery platforms. With the utilization of these technologies, these drawbacks of CP have been resolved to a large extent to reestablish this moiety. This article explores the physicochemical properties and mechanism of action of CP. Additionally, an attempt has been made to discover and highlight the possible features of the novel nanosystems, including nanoemulsions, nanosponges, solid lipid nanoparticles, nanostructured lipid carriers, and nanogels, reported for CP. The stability and safety concerns of CP, along with its commercial status, are also discussed. MDPI 2022-02-09 /pmc/articles/PMC8877216/ /pubmed/35214115 http://dx.doi.org/10.3390/pharmaceutics14020383 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Nair, Anroop B. Kumar, Sunil Dalal, Pooja Nagpal, Chahat Dalal, Sweta Rao, Rekha Sreeharsha, Nagaraja Jacob, Shery Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update |
title | Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update |
title_full | Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update |
title_fullStr | Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update |
title_full_unstemmed | Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update |
title_short | Novel Dermal Delivery Cargos of Clobetasol Propionate: An Update |
title_sort | novel dermal delivery cargos of clobetasol propionate: an update |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877216/ https://www.ncbi.nlm.nih.gov/pubmed/35214115 http://dx.doi.org/10.3390/pharmaceutics14020383 |
work_keys_str_mv | AT nairanroopb noveldermaldeliverycargosofclobetasolpropionateanupdate AT kumarsunil noveldermaldeliverycargosofclobetasolpropionateanupdate AT dalalpooja noveldermaldeliverycargosofclobetasolpropionateanupdate AT nagpalchahat noveldermaldeliverycargosofclobetasolpropionateanupdate AT dalalsweta noveldermaldeliverycargosofclobetasolpropionateanupdate AT raorekha noveldermaldeliverycargosofclobetasolpropionateanupdate AT sreeharshanagaraja noveldermaldeliverycargosofclobetasolpropionateanupdate AT jacobshery noveldermaldeliverycargosofclobetasolpropionateanupdate |